Compounds that bind macrophage migration inhibitory factor

Case ID:
Web Published:

Technology Summary:

Recombinant polypeptide composition for treatment of progressive multiple sclerosis (MS). This peptide approach selectively blocks key pro-inflammatory factors that could stop MS progression. Derived from CD74, the new composition competes for binding of the CD74 ligand, macrophage migration inhibitory factor (MIF). CD74 is a chaperone that assists with the folding and trafficking of Class II MHC (Major Histocompatibility Complex) while MIF has been implicated in the pathogenesis of progressive multiple sclerosis.

Background: MIF acts on the immune system to recruit inflammatory factors within injured tissues, including the central nervous system in MS. Upon binding to its receptor, CD74, MIF activates pathways to promote inflammation. The new OHSU composition competes with MIF to bind to CD74 thereby inhibiting inflammation.


•       A therapeutic to block inflammation driven by MIF interactions with CD74;

•       An alternative to a MIF specific mAbs as the new OHSU composition is more selective in its ability to block MIF signaling through CD74.


Patent Information:
For Information, Contact:
Anne Carlson
Technology Development Manager
Oregon Health & Science University
Arthur Vandenbark
Gil Benedek
Roberto Meza-Romero
Therapeutics - Immunology
© 2021. All Rights Reserved. Powered by Inteum